High-throughput molecular and histopathologic profiling of tumor tissue in a novel transplantable model of murine neuroblastoma: New tools for pediatric drug discovery

Cancer Investigation

Volumn 30, Issue 5, 2012, Pages 343-363

  Stauffer, Jimmy K ^a   Orentas, Rimas J ^a   Lincoln, Erin ^b   Khan, Tahira ^a   Salcedo, Rosalba ^a   Hixon, Julie A ^a   Back, Timothy C ^b   Wei, Jun S ^c   Patidar, Rajesh ^c   Song, Young ^c   Hurd, Laura ^c   Tsokos, Maria ^a   Lai, Edwin W ^d   Eisenhofer, Graeme ^d   Weiss, William ^e   Khan, Javed ^a,c   Wigginton, Jon M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c Advanced Technology Center   (United States)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Microenvironment; Mouse model; MYCN; Neuroblastoma

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; ADRENALIN; BUCICLOVIR; CATECHOLAMINE; CD31 ANTIGEN; CHROMOGRANIN; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE 4; DOPA; DOPAMINE; NEURON SPECIFIC ENOLASE; NORADRENALIN; SYNAPTOPHYSIN; TYROSINE 3 MONOOXYGENASE;

ADRENAL GLAND; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; GENETIC ASSOCIATION; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; IMMUNE EVASION; IMMUNOHISTOCHEMISTRY; MOUSE; NEUROBLASTOMA; NEUROFILAMENT; NONHUMAN; PRIORITY JOURNAL; TISSUE MICROARRAY; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

ANIMALS; ANTIGENS, CD31; APOPTOSIS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 4; DRUG DISCOVERY; GENE EXPRESSION PROFILING; GENES, TUMOR SUPPRESSOR; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PRINCIPAL COMPONENT ANALYSIS; TISSUE ARRAY ANALYSIS;

EID: 84861070743     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2012.664670     Document Type: Article

References (110)

1. Brodeur GM,Maris JM. Neuroblastoma. In Principles and Practice of Pediatric Oncology, PA Pizzo and DG Poplack (eds.). Philadelphia, PA: LippincottWilliam &Wilkins, 2002:895-938.
2. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-216. (Pubitemid 37328872)
3. Goldsby RE,Matthay KK. Neuroblastoma: evolving therapies for a disease with many faces. Paediatr Drugs 2004;6:107-122.
4. Weinstein JL, Katzenstein HM, Cohn SL. Advances in the diagnosis and treatment of neuroblastoma. Oncologist 2003;8:278-292. (Pubitemid 36648814)
5. Wigginton J. Preclinical animal models for the investigation of biologic approaches for the therapy of neuroblastoma. In Renal and Adrenal Tumors: Biology and Management, A Belldegrun, R Figlin, D Vaughn, A Ritchie, and T Oliver (eds.). New York: Oxford University Press, 2003, 144-155.
6. Lode HN, Dreier T, Xiang R, Varki NM, Kang AS, Reisfeld RA. Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma. Proc Natl Acad Sci U S A 1998;95:2475-2480. (Pubitemid 28145966)
7. Lode HN, Xiang R, Varki NM, Dolman CS, Gillies SD, Reisfeld RA. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst 1997;89:1586-1594. (Pubitemid 27479718)
8. Katsanis E, Blazar BR, Bausero MA, Gunther R, Anderson PM. Retroperitoneal inoculation of murine neuroblastoma results in a reliable model for evaluation of the antitumor immune response. J Pediatr Surg 1994;29:538-542. (Pubitemid 24132662)
9. Katsanis E, Bausero MA, Panoskaltsis-Mortari A, Dancisak BB, Xu Z, Orchard PJ, Davis CG, Blazar BR. Irradiation of singly and doubly transduced murine neuroblastoma cells expressing B7-1 and producing interferon-gamma reduces their capacity to induce systemic immunity. Cancer GeneTher 1996;3:75-82. (Pubitemid 126732426)
10. Fowler C, Zimmer C, Boghaert E, Thomas M, Zimmer S. Metastasis of C1300 and TBJ murine neuroblastomas correlates with expression of matrix metalloproteinases. Cancer Lett 1995;93:171-177.
11. Shimizu T, Berhanu A, Redlinger RE, , Watkins S, Lotze MT, arksdale EM, Interleukin-12 transduced dendritic cells induce regression of established murine neuroblastoma. J Pediatr Surg 2001;36:1285-1292. (Pubitemid 32705726)
12. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-1124. (Pubitemid 14106392)
13. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE,Wong KY, Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-1116. (Pubitemid 16216827)
14. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997;16:2985-2995. (Pubitemid 27234938)
15. Okabe M, Ikawa M, Kominami K, Nakanishi T, Nishimune Y. "Green mice" as a source of ubiquitous green cells. FEBS Lett 1997;407:313-319. (Pubitemid 27199450)
16. Khan T, Hixon JA, Stauffer JK, Lincoln E, Back TC, Brenner J, Lockett S, Nagashima K, Powell D, Wigginton JM. Therapeutic modulation of Akt activity and antitumor efficacy of interleukin- 12 against orthotopic murine euroblastoma. J Natl Cancer Inst 2006;98:190-202. (Pubitemid 43205481)
17. Salcedo R, Stauffer JK, Lincoln E, Back TC, Hixon JA, Hahn C, Shafer-Weaver K, Malyguine A, Kastelein R, Wigginton JM. IL-27 mediates complete regression of orthotopic primary and metastaticmurine neuroblastoma tumors: role for CD8+T cells. J Immunol 2004;173:7170-7182. (Pubitemid 39628152)
18. Motoike T, Loughna S, Perens E, Roman BL, Liao W, Chau TC, Richardson CD, Kawate T, Kuno J, Weinstein BM, Stainier DY, Sato TN. Universal GFP reporter for the study of vascular development. Genesis 2000;28:75-81.
19. Eisenhofer G, Goldstein DS, Stull R, Keiser HR, Sunderland T, Murphy DL, Kopin IJ. Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin Chem 1986;32:2030-2033.
20. Stauffer JK, Khan T, Salcedo R, Hixon JA, Lincoln E, Back TC, Wigginton JM. Multicolor fluorescence-based approaches for imaging cytokine-induced alterations in the neovascularization, growth, metastasis, and apoptosis of murine neuroblastoma tumors. J Immunother 2006;29:151-164.
21. Wigginton JM,Gruys E, Geiselhart L, Subleski J, Komschlies KL, Park JW, Wiltrout TA, Nagashima K, Back TC, Wiltrout RH. IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest 2001;108:51-62. (Pubitemid 32634922)
22. Wei J, Khan J. Purification of total RNA from mammalian cells and tissues. In DNA Microarays: A Molecular Cloning Manual, D Botwell and J Sambrook (eds.). Cold Spring Harbor, NY: Cold Spring Harbor Press, 2002, 110-119.
23. Sotiriou C,Khanna C, Jazaeri AA, Petersen D, Liu ET. Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays. J Mol Diagn 2002;4:30-36. (Pubitemid 44698433)
24. Hegde P, Qi R, Abernathy K, Gay C, Dharap S, Gaspard R, Hughes JE, Snesrud E, Lee N, Quackenbush J. A concise guide to cDNA microarray analysis. Biotechniques 2000;29:548-550; 52-54, 56 passim.
25. Wei JS, Greer BT, Westermann F, Steinberg SM, Son CG, Chen QR, Whiteford CC, Bilke S, Krasnoselsky AL, Cenacchi, N, Catchpoole D, Berthold F, Schwab M, Khan J. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res 2004;64:6883-6891. (Pubitemid 39330995)
26. Krasnoselsky AL, Whiteford CC, Wei JS, Bilke S, Westermann F, Chen QR, Khan J. Altered expression of cell cycle genes distinguishes aggressive neuroblastoma. Oncogene 2005;24:1533-1541. (Pubitemid 40396083)
27. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-5121. (Pubitemid 32397092)
28. Meitar D, Crawford SE, Rademaker AW, Cohn SL. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 1996;14:405-414. (Pubitemid 26051001)
29. Stickler GB, Flock EV. Neuroblastoma and ganglioneuroblastoma: associated increased urinary excretion of catecholamines. Cancer Chemother Rep 1962;16:439-442.
30. Voorhess ML, Gardner LI. The value of serial catecholamine determinations in children with neuroblastoma. Pediatrics 1962;30:241-246.
31. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, RamsayNK, Swift P, ShimadaH, Black CT, Brodeur GM,Gerbing RB, Reynolds CP. Treatment of high-risk neuroblastomawith intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-1173. (Pubitemid 29480654)
32. Gilman AL, OzkaynakMF,Matthay KK, Krailo M, Yu AL, Gan J, Sternberg A, Hank JA, Reaman GH, Sondel PM. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. J Clin Oncol 2009;27:85-91.
33. Shimada H, Umehara S, Monobe Y, Hachitanda Y, Nakagawa A, Goto S, Gerbing RB, Stram DO, Lukens JM, Mathtay KK. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001;92:2451-2461. (Pubitemid 33029092)
34. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B. erminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 1999;86:349-363. (Pubitemid 29327593)
35. LaBrosse EH, Comoy E, Bohuon C, Zucker JM, Schweisguth O. Catecholaminemetabolism in neuroblastoma. J Natl Cancer Inst 1976;57:633-638.
36. Pritchard J, Barnes J, Germond S,HartmanO, de Kraker J, Lewis I, Lockwood L,Wallendszus K. Stage and urinary catecholamine metabolite excretion in neuroblastoma. European Neuroblastoma Study Group. Lancet 1989;2:514-515. (Pubitemid 19209185)
37. Ribatti D, Ponzoni M. Antiangiogenic strategies in neuroblastoma. Cancer Treat Rev 2005;31:27-34. (Pubitemid 40246988)
38. Shusterman S, Maris JM. Prospects for therapeutic inhibition of neuroblastoma angiogenesis. Cancer Lett 2005;228:171-179. (Pubitemid 41188439)
39. Streck CJ, Ng CY, Zhang Y, Zhou J, Nathwani AC, Davidoff AM. Interferon-mediated anti-angiogenic therapy for neuroblastoma. Cancer Lett 2005;228:163-170. (Pubitemid 41188438)
40. Wang B, Xiao Y, Ding BB, Zhang N, Yuan X, Gui L, Qian KX, Duan S, Chen Z, Rao Y, Geng JG. Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity. Cancer Cell 2003;4:19-29. (Pubitemid 36904158)
41. Wong K, Park HT, Wu JY, Rao Y. Slit proteins: molecular guidance cues for cells ranging from neurons to leukocytes. Curr Opin Genet Dev 2002;12:583-591. (Pubitemid 35013540)
42. Wang KH, Brose K, Arnott D, Kidd T, Goodman CS, Henzel W, Tessier-LavigneM. Biochemical purification of a mammalian slit protein as a positive regulator of sensory axon elongation and branching. Cell 1999;96:771-784. (Pubitemid 29165081)
43. WuW,WongK,Chen J, Jiang Z, Dupuis S,Wu JY,Rao Y. Directional guidance of neuronal migration in the olfactory system by the protein Slit. Nature 1999;400:331-336. (Pubitemid 29344191)
44. Gao AG, Lindberg FP, Finn MB, Blystone SD, Brown EJ, Frazier WA. Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin. J Biol Chem 1996;271:21-24. (Pubitemid 26026555)
45. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A 1990;87:6624-6628.
46. Yang QW, Liu S, Tian Y, Salwen HR, Chlenski A, Weinstein J, et al. Methylation-associated silencing of the thrombospondin- 1 gene in human neuroblastoma. Cancer Res 2003;63:6299-6310. (Pubitemid 37255177)
47. Castle VP, Ou X, O'Shea S, Dixit VM. Induction of thrombospondin 1 by retinoic acid is important during differentiation of neuroblastoma cells. J Clin Invest 1992;90:1857-1863.
48. Miyashita M, Ohnishi H, Okazawa H, Tomonaga H, Hayashi A, Fujimoto TT, Furuya N, Matozaki T. Promotion of neurite and filopodium formation by CD47: roles of integrins, Rac, and Cdc42. Mol Biol Cell 2004;15:3950-3963. (Pubitemid 38989727)
49. Handsley MM, Edwards DR. Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer 2005;115:849-860. (Pubitemid 40791824)
50. Stetler-Stevenson WG, Seo DW. TIMP-2: an endogenous inhibitor of angiogenesis. Trends Mol Med 2005;11:97-103. (Pubitemid 40348986)
51. Ara T, Fukuzawa M, Kusafuka T, Komoto Y, Oue T, Inoue M, Okada A. Immunohistochemical expression ofMMP-2,MMP-9, and TIMP-2 in neuroblastoma: association with tumor progression and clinical outcome. J Pediatr Surg 1998;33:1272-1278.
52. Spurbeck WW, Ng CY, Strom TS, Vanin EF, Davidoff AM. Enforced expression of tissue inhibitor ofmatrixmetalloproteinase- 3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model. Blood 2002;100: 3361-3368. (Pubitemid 35217088)
53. Spurbeck WW, Ng CY, Vanin EF, Davidoff AM. Retroviral vector-producer cell-mediated in vivo gene transfer of TIMP-3 restricts angiogenesis and neuroblastoma growth in mice. Cancer GeneTher 2003;10:161-167. (Pubitemid 36348676)
54. Iolascon A, Borriello A, Giordani L, Cucciolla V, Moretti A, Monno F, Criniti V,Marzullo A, CriscuoloM, Garione FD. Caspase 3 and 8 deficiency in human neuroblastoma. Cancer Genet Cytogenet 2003;146:41-47. (Pubitemid 37117433)
55. Teitz T,Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Lahti JM, Kidd VJ. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas ith amplification of MYCN. Nat Med 2000;6:529-535. (Pubitemid 30305902)
56. Koizumi H, Ohkawa I, Tsukahara T, Momoi T, Nakada K, Uchikoshi T. Apoptosis in favourable neuroblastomas is not dependent on Fas (CD95/APO-1) expression but on activated caspase 3 (CPP32). J Pathol 1999;189:410-415. (Pubitemid 29489227)
57. Adida C, Berrebi D, PeuchmaurM, Reyes-MugicaM, AltieriDC. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 1998;351:882-883. (Pubitemid 28121185)
58. Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E, Ohira M, Hashizume K, Kobayashi H, Kaneko Y, Nakagawara A. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000;19:617-623. (Pubitemid 30102912)
59. van Golen CM, Castle VP, Feldman EL. IGF-I receptor activation and BCL-2 overexpression prevent early apoptotic events in human neuroblastoma. Cell Death Differ 2000;7:654-665. (Pubitemid 30456171)
60. Poulaki V, Mitsiades N, Romero ME, Tsokos M. Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and Bcl-2. Cancer Res 2001;61:4864-4872. (Pubitemid 32691903)
61. Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, Foster P, Camoratto AM, Evans AE, Brodeur GM. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 2002;62:6462-6466. (Pubitemid 35364107)
62. Kim S, Kang J, HuW, Evers BM, Chung DH.Geldanamycin decreases Raf-1 and Akt levels and induces apoptosis in neuroblastomas. Int J Cancer 2003;103:352-359. (Pubitemid 36076428)
63. Kim S, Kang J, Qiao J, Thomas RP, Evers BM, Chung DH. Phosphatidylinositol 3-kinase inhibition down-regulates survivin and facilitates TRAIL-mediated apoptosis in neuroblastomas. J Pediatr Surg 2004;39:516-521. (Pubitemid 38500368)
64. Shankar SL, Mani S, O'Guin KN, Kandimalla ER, Agrawal S, Shafit-Zagardo B. Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways. J Neurochem 2001;79:426-436. (Pubitemid 32988959)
65. Bown N, Lastowska M, Cotterill S, O'Neill S, Ellershaw C, Roberts P, Lewis I, Pearson AD. 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group.Med Pediatr Oncol 2001;36:14-19. (Pubitemid 32052988)
66. LastowskaM, Cotterill S, Bown N, Cullinane C, Variend S, Lunec J, Strachan T, Pearson AD, Lackson MS. Breakpoint position on 17q identifies the most aggressive neuroblastoma tumors. Genes Chromosomes Cancer 2002;34:428-436. (Pubitemid 34787464)
67. Pratt MA, Niu M, White D. Differential regulation of protein expression, growth and apoptosis by natural and synthetic retinoids. J Cell Biochem 2003;90:692-708. (Pubitemid 37392461)
68. Goldsmith KC, Hogarty MD. Targeting programmed cell death pathways with experimental therapeutics: opportunities in highrisk neuroblastoma. Cancer Lett 2005;228:133-141. (Pubitemid 41188435)
69. Zaffaroni N, Pennati M, Daidone MG. Survivin as a target for new anticancer interventions. J Cell Mol Med 2005;9:360-372.
70. Emanuel S, Rugg CA, Gruninger RH, Lin R, Fuentes-Pesquera A, Connolly PJ, Wetter SK, Hollister B, Kruger WW, Napier C, Jolliffe, Middleton S.A. The in vitro and in vivo effects of JNJ- 7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res 2005;65:9038-9046. (Pubitemid 41377396)
71. Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH, 3rd, Treiber DK, Patel HK, Zarrinkar PP, Lockart DJ, awyers CL, Kuriyan J. Structure of the kinase domain of an imatinib-resistant Ablmutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 2006;66:1007-1014. (Pubitemid 43168337)
72. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Mloney A, Raynaud F, Campbell M, Walton M, Lakhani, Kaye S, Workman P, Judson I. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17- demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23:4152-4161. (Pubitemid 46211321)
73. Xiao HH, Makeyev Y, Butler J, Vikram B, Franklin WA. 7- Hydroxystaurosporine (UCN-01) preferentially sensitizes cells with a disrupted TP53 to gamma radiation in lung cancer cell lines. Radiat Res 2002;158:84-93. (Pubitemid 34728915)
74. Eckerdt F, Yuan J, Strebhardt K. Polo-like kinases and oncogenesis. Oncogene 2005;24:267-276. (Pubitemid 40188607)
75. Gumireddy K, Reddy MV, Cosenza SC, Boominathan R, Baker SJ, Papathi N, Jiang J, Holland J, Reddy EP. ON01910, a non- ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 2005;7:275-286. (Pubitemid 40568686)
76. Shapiro GI. Preclinical and clinical development of the cyclindependent kinase inhibitor flavopiridol. Clin Cancer Res 2004;10:4270s-4275s. (Pubitemid 38812461)
77. Swanton C. Cell-cycle targeted therapies. Lancet Oncol 2004; 5:27-36. (Pubitemid 38072557)
78. Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barrett JC. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995;268:884-886.
79. Cowin P, Rowlands TM, Hatsell SJ. Cadherins and catenins in breast cancer. Curr Opin Cell Biol 2005;17:499-508. (Pubitemid 41267164)
80. Nelson WJ,Nusse R. Convergence ofWnt, beta-catenin, and cadherin pathways. Science 2004;303:1483-1487. (Pubitemid 38314410)
81. Wheelock MJ, Johnson KR. Cadherins as modulators of cellular phenotype. Annu Rev Cell Dev Biol 2003;19:207-235. (Pubitemid 37487348)
82. Reed CC, Waterhouse A, Kirby S, Kay P, Owens RT, McQuillan DJ, Iozzo RV. Decorin prevents metastatic spreading of breast cancer. Oncogene 2005;24:1104-1110. (Pubitemid 40313888)
83. Ikeyama S, Koyama M, Yamaoko M, Sasada R, Miyake M. Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA. J Exp Med 1993;177:1231-1237. (Pubitemid 23117114)
84. Cox JL, Sexton PS, Green TJ, Darmani NA. Inhibition of B16 melanoma metastasis by overexpression of the cysteine proteinase inhibitor cystatin C. Melanoma Res 1999;9:369-374. (Pubitemid 29407069)
85. Aryee DN, Ambros I, Ambros PF,Muehlbacher K, Luegmayr A, Yoshie O, Kovar Het al. Frequent low level expression in Ewing sarcoma family tumors and widespread absence of themetastasis suppressor KAI1/CD82 in neuroblastoma. Pediatr Res 2002;52: 279-285. (Pubitemid 34827250)
86. Fazili Z, SunW, Mittelstaedt S, Cohen C, Xu XX. Disabled-2 inactivation is an early step in ovarian tumorigenicity. Oncogene 1999;18:3104-3113. (Pubitemid 29261231)
87. Hsieh SY, Hsieh PS, Chiu CT, Chen WY. Dickkopf-3/REIC functions as a suppressor gene of tumor growth. Oncogene 2004;23:9183-9189.
88. Dang DT, Chen X, Feng J, Torbenson M, Dang LH, Yang VW. Overexpression of Kruppel-like factor 4 in the human colon cancer cell line RKO leads to reduced tumorigenecity. Oncogene 2003;22:3424-3430. (Pubitemid 36713740)
89. Li Y, Pei J, Xia H, Ke H, Wang H, Tao W. Lats2, a putative tumor suppressor, inhibits G1/S transition. Oncogene 2003;22:4398-4405. (Pubitemid 36897970)
90. Deng Y, Yao L, Chau L, Ng SS, Peng Y, Liu X, Au WS,Wang J, Li F, Ji S, Han H, Lie X, Li Q, Kung HF, Leung SY, Lin MC. NMyc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int J Cancer 2003;106:342-347. (Pubitemid 36870394)
91. Rossi M, Sayan AE, Terrinoni A, Melino G, Knight RA. Mechanism of induction of apoptosis by p73 and its relevance to neuroblastoma biology. Ann N Y Acad Sci 2004;1028: 143-149. (Pubitemid 40361818)
92. Terrinoni A, RanalliM, Cadot B, Leta A, BagettaG,Vousden KH, Melino G. p73-alpha is capable of inducing scotin and ER stress. Oncogene 2004;23:3721-3725. (Pubitemid 38658440)
93. Karim R, Tse G, Putti T, Scolyer R, Lee S. The significance of the Wnt pathway in the pathology of human cancers. Pathology 2004;36:120-128. (Pubitemid 38507872)
94. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 2004;5:691-701. (Pubitemid 39150127)
95. BlancE, RouxGL,BenardJ,RaguenezG.LowexpressionofWnt- 5a gene is associated with high-risk neuroblastoma. Oncogene 2005;24:1277-1283.
96. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD. Demonstration of an interferon gammadependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998;95:7556-7561. (Pubitemid 28293291)
97. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 1994;153:1697-1706. (Pubitemid 24251114)
98. Wigginton JM, Lee JK, Wiltrout TA, AlvordWG, Hixon JA, Subleski J, Back TC, Wiltrout RH. Synergistic engagement of an ineffective endogenous anti-tumor immune response and induction of IFN-gamma and Fas-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2. J Immunol 2002;169:4467-4474. (Pubitemid 35178223)
99. Hisada M, Kamiya S, Fujita K, Belladonna ML, Aoki T, Koyanagi Y, Mizugucho J, Yoshito T. Potent antitumor activity of interleukin-27. Cancer Res 2004;64:1152-1156. (Pubitemid 38176923)
100. Schroder K,Hertzog PJ, Ravasi T,HumeDA. Interferon-gamma: an overview of signals,mechanisms and functions. J Leukoc Biol 2004;75:163-189.
101. Takeda A, Hamano S, Yamanaka A, Hanada T, Ishibashi T, Mak TW, Yoshimura A, Yoshida H. Cutting edge: role of IL-27/WSX- 1 signaling for induction of T-bet through activation of STAT1 during initialTh1 commitment. J Immunol 2003;170:4886-4890. (Pubitemid 36554716)
102. Parham C, ChiricaM, Timans J, Vaisberg E, TravisM, Cheung J, Pflanz S, Zhang R, Singh KP, Vega F, To W, Wagner J, O'Farrell AM, McClanahan T, Zurawski S, Hannum C, Gorman D, Rennick DM, Kastelein RA, de Wall Malefyt R, Moore KW. A receptor for the heterodimeric cytokine IL-23 is composed of IL- 12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002;168:5699-5708. (Pubitemid 34556153)
103. WatfordWT, Hissong BD, Bream JH, Kanno Y, Muul L, O'Shea JJ. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev 2004;202:139-156. (Pubitemid 39576910)
104. Lampson LA, Fisher CA. Weak HLA and beta 2-microglobulin expression of neuronal cell lines can be modulated by interferon. Proc Natl Acad Sci U S A 1984;81:6476-6480. (Pubitemid 15221857)
105. Whelan JP, Chatten J, Lampson LA. HLA class I and beta 2-microglobulin expression in frozen and formaldehydefixed paraffin sections of neuroblastoma tumors. Cancer Res 1985;45:5976-5983. (Pubitemid 16218621)
106. Fischer M, Oberthuer A, Brors B, Kahlert Y, Skowron M, Voth H, Warnat P, Emestus K, Berthold F. Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome. Clin Cancer Res 2006;12:5118-5128. (Pubitemid 44453339)
107. Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J, Swerts K, Bravo S, Scaruffi P, Tonini GP, De Bernardi B, Noguera R, Piqueras M, Canete A, Castel V, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Michon J, Combaret V, Fischer M, Oberthuer A, Ambros PF, Beiske K, Denard J, Marques B, Rubie H, Kohler J, Potschger U, Ladenstain R, Hogarty MD, McGrady P, London WB, Laureys G, Speleman F, Vandesompele J. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol 2009;10:663-671.
108. Abel F, Dalevi D, Nethander M, Jornsten R, De Preter K, Vermeulen J, Stallings R, Kogner P, Maris J, Nilsson S. A 6-gene signature identifies four molecular subgroups of neuroblastoma. Cancer Cell Int 2011;11:9.
109. Hackett CS, Hodgson JG, Law ME, Fridlyand J, Osoegawa K, de Jong PJ, Nowak NJ, Pinkel D, Albertson DG, Jain A, Jenkins R, Gray JW, Weiss WA. Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. Cancer Res 2003;63:5266-5273. (Pubitemid 37139840)
110. Cheng AJ, Cheng NC, Ford J, Smith J, Murray JE, Flemming C, Lastowska M, Jackson MS, Mackett CS, Weiss WA, Marshall GM, Kees UR, Norris MD, Haber M. Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma. Eur J Cancer 2007;43:1467-1475. (Pubitemid 46881125)